The Reflux Company provides patient-centered diagnostic and therapeutic solutions for individuals suffering from gastroesophageal reflux. The company offers a portfolio of FDA-cleared products, including the Restech Dx-pH upper airway test, the Stretta incision-free procedure for chronic GERD, the Reflux Band nighttime sleep device, and the at-home PepsinCheck saliva test.
Subscribe to see Reflux Co’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Reflux Co is a medical devices & healthcare company headquartered in San Diego, United States. Its most recent funding round raised $525,000 in April 2026. Xcout tracks 11 named people at Reflux Co, including Mark Clark (Chief Financial Officer).
As of 20 November 2026. Source: Xcout Intel.
5 more named people on record for Reflux Co, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $525,000 | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of Reflux Co's closest competitors — see the full list of competitors and alternatives →
EnteroTrack, LLC provides the Esophageal String Test (EST) using its EnteroTracker device, offering a minimally invasive, non-endoscopic tool for clinicians to collect upper gastrointestinal samples and monitor Eosinophilic Esophagitis (EoE) activity in patients. The office-based procedure helps assess mucosal inflammation and biomarkers over time, potentially reducing the need for repeated endoscopies.
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Origin Sciences is a medical technology company based in the UK that develops innovative devices and tests to aid in the detection and diagnosis of gastrointestinal diseases.
University Medical Devices, Inc. designs and manufactures specimen collection systems for diagnostic testing, focusing on solutions for respiratory illnesses. The company's flagship product, MicroWash, is a less invasive nasal lavage device intended to improve patient comfort and laboratory sample quality.
Established in Toronto, Canada, in 2001 as The Jenex Corporation before rebranding to Therma Bright Inc. in February 2018, Therma Bright Inc. specializes in creating and distributing various medical and consumer health products. Their diverse offerings include rapid COVID-19 diagnostic tests like AcuVid, which screens for both antigens and antibodies. For pain relief, they provide devices such as Benepod, a hot and cold contrast therapy system designed to manage discomfort without medication. The company also addresses circulatory issues with Venowave, a medical compression pump aimed at mitigating symptoms associated with poor circulation. Furthermore, Therma Bright caters to the cosmeceutical industry with products like InterceptCS, a cold sore prevention system utilizing safe, controlled topical heat, and TherOZap, a thermal device that alleviates the pain, itching, and inflammation from insect bites and stings by reducing the inflammatory response. Their clientele spans both individual consumers and healthcare practitioners.
PAVmed Inc. operates as a U.S.-based medical technology firm. Its principal commercialized products include CarpX, a percutaneous device designed to address carpal tunnel syndrome. Other key offerings are EsoCheck, an esophageal cell collection device vital for the early detection of esophageal adenocarcinoma and Barrett's Esophagus (BE), and EsoGuard, a specialized bisulfite-converted next-generation sequencing DNA assay. The company's extensive development pipeline further encompasses EsoCure, an esophageal ablation device intended to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; and NextFlo, a disposable infusion platform technology. Also in development are the Veris cancer healthcare platform, which features an intelligent vascular port for combined remote monitoring and data analytics, alongside Veris cardiac monitors. Additional innovations include NextVent single-use ventilators, FlexMO medical circulatory support cannulas, DisappEAR resorbable pediatric ear tubes, and Solys for noninvasive glucose monitoring. Established in 2014, the enterprise originally traded as PAXmed Inc. before rebranding to PAVmed Inc. in April 2015. Its corporate headquarters are located in New York, New York.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about Reflux Co? Suggest a correction · Work at Reflux Co? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.